Gustavo de Ugarte

Analytical Sciences and Technology

Role: Sr Director Asat -global Lead at Vaxcyte
Location: Sanford, NC, US
LinkedIn followers: 500 followers

Research & DevelopmentView LinkedIn profile

Experience

Sr Director Asat -global Lead
Vaxcyte
Oct 2024 — Present · San Carlos, CA, US

Education

Park University
BA, Chemistry, Biology, Mathematics
1995 — 2000
Brown University
Master of Arts (M.A.), Biology/Biological Sciences, General
2009 — 2012
Temple University School of Pharmacy
Master of Science - MS, Regulatory Affairs and Quality Assurance

Skills

Validation
Capa
Quality System
Technology Transfer
Hplc
Lims
Change Control
Analytical Chemistry
Quality Assurance
Chromatography
Pharmaceutical Industry
Sop
Fda
21 Cfr Part 11
Glp
Gmp

Contact information

Verified work emails, personal emails, and direct dials — unlocked in one click.

Work email
•••••@vaxcyte.com
Personal email
•••••@•••••.com
Direct dial
+18•••••••51

Unlock verified contacts

Free to start · No credit card required

Current company

Vaxcyte

Biotechnology Research · 580 employees · Founded 2013 · San Carlos, California, United States

Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. VAX-31, a 31-valent pneumococcal conjugate vaccine (PCV) candidate being evaluated in the OPUS Phase 3 adult clinical program and in a Phase 2 infant clinical program, is being developed for the prevention of invasive pneumococcal disease (IPD) and is the broadest-spectrum PCV candidate in the clinic today. VAX-24, a 24-valent PCV candidate, is designed to cover more serotypes than any infant PCV on-market. VAX-31 and VAX-24 are designed to improve upon standard-of-care PCVs by covering the serotypes in circulation that cause a significant portion of IPD and are associated with high case-fatality rates, antibiotic resistance and meningitis, while maintaining coverage of previously circulating strains. VAX-XL, in earlier-stage development, also leverages the Company’s carrier-sparing, site-specific conjugation technology with the aim of further expanding coverage to deliver the broadest-spectrum candidate in the Company’s PCV franchise. Vaxcyte is re-engineering the way highly complex vaccines are made through XpressCF®, its cell-free protein synthesis platform exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company’s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to develop high-fidelity vaccines with enhanced immunological benefits. Vaxcyte’s pipeline also includes VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections, and VAX-GI, a vaccine candidate designed to prevent Shigella.

vaxcyte.com

Find verified contacts for anyone on LinkedIn

Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.

Start for free See how it works

Free plan included · No credit card required

This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.

Experience

Sr Director Asat -global Lead

Education

Park University

Brown University

Temple University School of Pharmacy

Skills

Find verified contacts for anyone on LinkedIn